FindTrial
Sign In

Treatment Group:Decitabine in combination with melphalan

2 trials

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Conditions

Meet the diagnostic criteria for Myelodysplastic Syndromes (MDS) according to the WHO-2022 classification of myeloid neoplasmsNewly diagnosed patients confirmed as myelodysplastic syndrome (MDS) with IB-1 or IB-2 according to the WHO-2022 classification

Phase 2

A phase II clinical study evaluating the efficacy and safety of Decitabine combined with Melphalan in newly diagnosed MDS-IB
Active, not recruitingChiCTR2500115218
The FIrst Affiliated Hospital, College of Medicine, Zhejiang UniversityNewly diagnosed patients confirmed as myelodysplastic syndrome (MDS) with IB-1 or IB-2 according to the WHO-2022 classification
Start: 2026-01-01Updated: 2026-01-05
DEMEL-1: A single-center, single-arm, phase II clinical study evaluating the efficacy and safety of Decitabine combined with low-dose Melphalan in patients with high-risk refractory myelodysplastic syndrome
Active, not recruitingChiCTR2500115432
The FIrst Affiliated Hospital, College of Medicine, Zhejiang UniversityMeet the diagnostic criteria for Myelodysplastic Syndromes (MDS) according to the WHO-2022 classification of myeloid neoplasms
Start: 2026-01-01Updated: 2026-01-05